Join our Webinar
January 22, 2021, 12:00 -12:40
Chief Scientific Officer Fluidigm Corporation
Mass Cytometry – a glance into the future
Impact of cytometry in infectious disease, cancer and immunology and how Fludigm will be enabling rapid growth in scientific discovery.
Fluidigm is committed to empowering the immunology community with research tools to interrogate immune cell function and tissue microenvironments in high dimensions. Using mass cytometry and genomics workflows, you can obtain unprecedented insight into cellular phenotypes and changes in rare cell populations.
Fluidigm technology can support the response to the global COVID-19 pandemic, enabling applications for SARS-CoV-2 virus detection and the monitoring of the immune system’s response to COVID-19 disease. To that end, our technologies are well-positioned for use in providing a robust public research response in support of policies and treatments aligned with local, state, and national recovery.
Fluidigm CyTOF® technology with the Maxpar® Direct Immune Profiling Assay™ provides best-in-class immune monitoring with the cost, flexibility, and consistency needed for standardized COVID-19 disease immune monitoring research. Imaging Mass Cytometry™ adds the capability of spatial visualization of the immune response in tissue samples. This newly developed technology enables the study of clinical outcomes and changes in the inflammatory or immune function directly from whole blood samples or tissues. In addition, labs around the world have leveraged the benefits of Fluidigm microfluidics for research and have implemented high-throughput lab-developed tests (LDT) for SARS-CoV-2 detection.
Whether you seek to target new biomarkers and pathways or optimize the effectiveness of an immunotherapy or vaccine, Fluidigm can help you reach your next research breakthrough. Together we’ll transform the future of care. Engage with us at fluidigm.com.
Life is complex. Simplify it. Standardized immune profiling with CyTOF technology.